Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Abstract Background Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), was evaluated in a phase II randomized, double-blind, placebo-controlled study to investigate the efficacy and safety in patien...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Peter C. Taylor, Didier Saurigny, Jiri Vencovsky, Tsutomu Takeuchi, Tadashi Nakamura, Galina Matsievskaia, Barbara Hunt, Thomas Wagner, Bernard Souberbielle, for the NEXUS Study Group
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2019-04-01
coleção:	Arthritis Research & Therapy
Assuntos:	Rheumatoid arthritis Namilumab GM-CSF
Acesso em linha:	http://link.springer.com/article/10.1186/s13075-019-1879-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!